Federal Circuit Clarifies the “Reasonable Expectation of Success” Required in Hatch-Waxman Obviousness Challenges

by Dechert LLP
Contact

Dechert LLP

The U.S. Federal Circuit recently clarified the standard that patent challengers must satisfy when attempting to invalidate patented inventions directed to new uses for known drugs. Although designated as a nonprecedential opinion, Genzyme Corporation v. Dr. Reddy’s Laboratories, Nos. 2016-2206, 2016-2207 (Fed. Cir. Dec. 18, 2017) provides important guidance for evaluating whether, for purposes of alleged obviousness, a prior art reference’s isolated, prophetic statement about a possible new use for a drug can support a finding that a person of ordinary skill in the art (“POSITA”) would have had a “reasonable expectation of success” in combining prior art references to achieve the claimed invention.

Obviousness and the Reasonable Expectation of Success

A claimed invention is unpatentable if the differences between it and the prior art “are such that the claimed invention as a whole would have been obvious . . . to a person having ordinary skill in the art to which the claimed invention pertains.” 35 U.S.C. § 103. If a patent’s claim limitations can be found individually in separate prior art references, a party seeking to invalidate the patent on obviousness grounds must show by clear and convincing evidence that a POSITA: (1) would have been motivated to combine the teachings of those prior art references to achieve the claimed invention; and (2) would have had a “reasonable expectation of success” in doing so. See Insite Vision Inc. v. Sandoz, Inc., 783 F.3d 853, 859 (Fed. Cir. 2015).

A Prior Art Reference’s Untested, Prophetic Hypothesis Does Not Provide a Reasonable Expectation of Success

In Genzyme, the patent-at-issue was directed to a method of sequentially administering two known drug products for a new use: mobilizing and harvesting stem cells. Under normal conditions, stem cells attach to bone marrow by forming a bond between a particular receptor on the stem cell (“CXCR-4”) and a protein produced in the bone marrow (“SDF-1”). The plaintiffs discovered, however, that administering the second drug product (plerixafor, a known drug) disrupts the bond between CXCR-4 and SDF-1, and releases stem cells into the bloodstream. The district court held that the defendants had failed to prove that the plaintiffs’ claimed invention was obvious.

On appeal, the key dispute concerned one of the factual findings required to prove obviousness under § 103: whether a POSITA would have had a “reasonable expectation of success” in combining the asserted prior art references. The primary reference was an article that evaluated the use of plerixafor to disrupt the bond between CXCR-4 and SDF-1 so as to release white blood cells—“and/or stem cells”—into the bloodstream for the purpose of treating HIV.

The district court had found that this article was not pertinent prior art because it focused on HIV treatment, not mobilizing and harvesting stem cells. The Federal Circuit, however, went one step further. It held that even if the article were pertinent prior art, a POSITA would not have had a reasonable expectation of success in applying the article’s teachings in the new and untested context of mobilizing and harvesting stem cells, notwithstanding the fact that it included the prophetic statement about the possible use of plerixafor for releasing stem cells into the bloodstream. The Federal Circuit characterized that statement as a mere “hypothesi[s] in an isolated sentence, without explanation,” and noted that the rest of the article’s seven pages focused on white blood cells, not stem cells. It found that, despite the mention of stem cells, a POSITA “would have recognized that [the article’s authors] never tested for the presence of stem cells[.]” And it concluded that the article’s hypothesis that plerixafor could be used to release stem cells into the bloodstream was not enough to provide a reasonable expectation of success in actually doing it.

The Federal Circuit reached similar conclusions with respect to the teachings of the other asserted prior art references, noting again that “a gap exists between using plerixafor to enhance [white blood cell] counts and for stem cell mobilization.”

Key Takeaway

Genzyme provides new, important guidance for Hatch-Waxman litigants in evaluating the “reasonable expectation of success” prong of the Federal Circuit’s obviousness analysis. Under Genzyme, a prior art reference’s passing prophetic statement that a known drug could be used to achieve a particular result is likely to be viewed as a mere untested hypothesis that is insufficient, without more, to sustain the required finding that a POSITA would have had a reasonable expectation of success in combining the prior art to achieve that result.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Written by:

Dechert LLP
Contact
more
less

Dechert LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.